Arcutis logo.png
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
March 09, 2023 08:00 ET | Arcutis Biotherapeutics, Inc.
Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national survey insights depicting disease burden, path to diagnosis...
Arcutis logo.png
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023 16:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 03, 2023 (GLOBE NEWSWIRE) --  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis logo.png
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023 16:02 ET | Arcutis Biotherapeutics, Inc.
Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growthSecured expanded commercial...
Arcutis logo.png
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
February 21, 2023 08:00 ET | Arcutis Biotherapeutics, Inc.
Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam would be the first topical drug for seborrheic...
Arcutis logo.png
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
February 08, 2023 08:00 ET | Arcutis Biotherapeutics, Inc.
Quarterly investor conference call and webcast scheduled for Tuesday, February 28 at 4:30 p.m. ETArcutis management will also participate in the Cowen 43rd Annual Healthcare Conference in March ...
Arcutis logo.png
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023 16:10 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis logo.png
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
January 14, 2023 04:00 ET | Arcutis Biotherapeutics, Inc.
During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or...
Arcutis logo.png
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2023 16:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis logo.png
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
December 19, 2022 08:00 ET | Arcutis Biotherapeutics, Inc.
Regulatory submission for the expanded indication is supported by data from two recently completed 4-week Maximal Usage Systemic Exposure (MUSE) studies in children ages 2 to 11 years with plaque...
Arcutis logo.png
Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
December 12, 2022 08:00 ET | Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and key secondary endpoints, consistent with positive topline results from the INTEGUMENT-1 trial released in NovemberFor the primary endpoint, 28.9% of individuals...